跳至主要内容
临床试验/NCT02710266
NCT02710266终止3 期

Evaluation of the Effect of Gabexate Mesilate in the Hepatocyte Protection After Liver Resection

Yonsei University1 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2012年2月24日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
终止
入组人数
2
试验地点
1
主要终点
Postoperative complications

研究概览

简要总结

Liver resection have been a primary treatment option for lesions found in the liver. With improvements in surgical technique and perioperative patient management, morbidity and mortality related to liver resection have been greatly reduced. However, many patients with hepatocellular carcinoma have underlying liver disease. Severity of underlying liver disease plays an important role in decision making of resection extent. Therefore, liver failure and decreased liver function following liver resection still remains to be an critical issue.

Postresection liver failure is generally defined by serum total bilirubin greater than 3mg/dL and prothrombin time of less than 50% of normal (INR >1.7). Pathophysiology of postresection liver failure is not yet well known. However, sepsis after liver resection, small-for-size syndrome (SFSS), and ischemia/reperfusion injury are known to have important roles in persistant liver injury after resection.

After a liver resection, kupffer cells are drastically decreased and innate immunity of the patient is also damaged. This process causes the patient to be vulnerable to infection. In addition, with continuous endotoxin secretion, dysfunction in kupffer cells are triggered and liver regeneration is affected.

Complex mechanisms leading to dysfunctional kupffer cells and apoptosis and necrosis of hepatocytes are mediated by neutrophils, complement, reactive oxygen species, and acute inflammatory cytokines.

Recent studies have reported on many promising effects of the synthetic protease inhibitor, such as Gabexate mesilate. These include antioxidant effect, inhibition of acute inflammatory cytokine reaction, and anticoagulatory property. Based on these effects, synthetic protease inhibitor have gained attention in the role of hepatocyte protection after liver resection.

Currently, there is a report on the hepatocyte protective effects of Gabexate Mesilate on ischemia/reperfusion injury caused by the Pringle maneuver. However, with the advances in surgical technique and equipment, many surgeons now perform liver resection without Pringle maneuver. Therefore, this study was designed to determine effects of Gabexate Mesilate in the liver resection performed without Pringle maneuver.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Double (Participant, Investigator)

入排标准

年龄范围
20 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All liver tumors that require resection of more than two segments of the liver.
  • Age ≥20 and ≤80
  • General performance status: the Karnofsky score> 70% or ECOG 0-1

排除标准

  • Hepatic duct reconstruction was performed
  • ASA (American society of anesthesiologists' physical status classification) score: ≥3
  • Patients with drug or alcohol addiction
  • Patients showing low compliance
  • Patients who not want to involve the clinical trial
  • Patients who are unable to read or understand the informed consent, sign a consent form (eg, mental retardation, blindness, illiteracy, foreign, etc.)

研究组 & 干预措施

Placebo group

Placebo Comparator

hepatectomy without Gabexate Mesilate

干预措施: hepatectomy with dextrose water (Drug)

Preoperative Gabexate Mesilate group

Experimental

Gabexate Mesilate administered from the preoperative day

干预措施: Preoperative Gabexate Mesilate group (Drug)

Intraoperative Gabexate Mesilate group

Experimental

Gabexate Mesilate administered from the operative day

干预措施: Intraoperative Gabexate Mesilate group (Drug)

结局指标

主要结局

Postoperative complications

时间窗: Within the first 30 days after surgery

次要结局

  • Liver function recovery time(4 weeks)
  • length of hospitalization(4 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验